Researcher

    Noël J-M Raynal , M.Sc. , Ph.D.

    noel.raynal@umontreal.ca
    Noël J-M Raynal
    Research Axis
    Immune Diseases and Cancer Axis
    Research Theme
    Cancers: mechanisms, new therapeutic approaches and disease outcomes
    Address
    CHUSJ

    Phone
    514 345-4931 #6763

    Phone
    #6763

    Title

    • Associate Professor, Department of Pharmacology and Physiology, Université de Montréal 
    • Principal investigator, CHU Sainte-Justine Research Center
    • Director of drug screening platform, CHU Sainte-Justine Research Center

    Education

    • Postdoctoral training, MD Anderson Cancer Center, Department of Leukemia, University of Texas and Fels Institute for Cancer Research and Molecular Biology, Temple University (2009-2013) 
    • Ph.D. in Biology, INRS-Institut Armand-Frappier, Université du Québec (2003-2008)
    • M.Sc. in Biology, Université du Québec à Montréal (2001-2003)
    • Undergraduate studies in Biochemistry, Université de Montpellier (2000)

    Lab research interests

    • Epigenetic therapy of pediatric cancers
    • Epigenetic drug screening
    • 3D cell culture

    Lab members

    • Mariya Kryvoshey, Master's Student
    • Emmanuel Sy, Master's Student
    • Walid Mardhy, Master's Student
    • Anaïs Darracq, Postdoctoral Fellow
    • Marielle Huot, Research Assistant
    • Nicolas Sgarioto, Research Assistant

    Publications

    • Repurposing proscillaridin A in combination with decitabine against embryonal rhabdomyosarcoma RD cells. Huot M, Caron M, Richer C, Djibo R, Najmanovich R, St-Onge P, Sinnett D, Raynal NJM. Cancer Chemother Pharmacol. 2021 Jul 31.
    • Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells. Dominici C, Sgarioto N, Yu Z, Sesma-Sanz L, Masson JY, Richard S, Raynal NJ. Clin Epigenetics. 2021 Mar 10;13(1):54.
    • Heart failure drug proscillaridin A targets MYC overexpressing leukemia through global loss of lysine acetylation. Da Costa EM, Armaos G, McInnes G, Beaudry A, Moquin-Beaudry G, Bertrand-Lehouillier V, Caron M, Richer C, St-Onge P, Johnson JR, Krogan N, Sai Y, Downey M, Rafei M, Boileau M, Eppert K, Flores-Díaz E, Haman A, Hoang T, Sinnett D, Beauséjour C, McGraw S, Raynal NJ. J Exp Clin Cancer Res. 2019 Jun 13;38(1):251
    • TACIMA-218: A Novel Pro-Oxidant Agent Exhibiting Selective Antitumoral Activity. Abusarah J, Cui Y, El-Hachem N, El-Kadiry AE, Hammond-Martel I, Wurtele H, Beaudry A, Raynal NJ, Robert F, Pelletier J, Jankovic M, Mercier F, Kamyabiazar S, Annabi B, Rafei M. Mol Cancer Ther. 2021 Jan;20(1):37-49.
    • Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer. Zhang H, Pandey S, Travers M, Sun H, Morton G, Madzo J, Chung W, Khowsathit J, Perez-Leal O, Barrero CA, Merali C, Okamoto Y, Sato T, Pan J, Garriga J, Bhanu NV, Simithy J, Patel B, Huang J, Raynal NJ, Garcia BA, Jacobson MA, Kadoch C, Merali S, Zhang Y, Childers W, Abou-Gharbia M, Karanicolas J, Baylin SB, Zahnow CA, Jelinek J, Graña X, Issa JJ. Cell. 2018 Nov 15;175(5):1244-1258.e26.
    • DNA Methylation-Targeted Drugs. Da Costa EM, McInnes G, Beaudry A, Raynal NJ. Cancer J. 2017 Sep/Oct;23(5):270-276.
    • Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome. Raynal NJ, Da Costa EM, Lee JT, Gharibyan V, Ahmed S, Zhang H, Sato T, Malouf GG, Issa JJ. Mol Cancer Ther. 2017 Feb;16(2):397-407
    • Targeting Calcium Signaling Induces Epigenetic Reactivation of Tumor Suppressor Genes in Cancer. Raynal NJ, Lee JT, Wang Y, Beaudry A, Madireddi P, Garriga J, Malouf GG, Dumont S, Dettman EJ, Gharibyan V, Ahmed S, Chung W, Childers WE, Abou-Gharbia M, Henry RA, Andrews AJ, Jelinek J, Cui Y, Baylin SB, Gill DL, Issa JP. Cancer Res. 2016 Mar 15;76(6):1494-505.
 

Grow Beyond our wildest dreams

With the support of donors like you, at the heart of the Grow Beyond campaign, we are leading healthcare teams towards the opportunities offered by science and new technologies, so that every child, no matter where in Quebec, has access to the unique expertise and know-how of CHU Sainte-Justine. Together, let's join forces for their future.

Grow Beyond with us.

Contact Us

514 345-4931

Légal

© 2006-2014 CHU Sainte-Justine.
All rights reserved.
Terms of Use, Confidentiality, Security

Avertissement

Les informations contenues dans le site « CHU Sainte-Justine » ne doivent pas être utilisées comme un substitut aux conseils d’un médecin dûment qualifié et autorisé ou d’un autre professionnel de la santé. Les informations fournies ici le sont à des fins exclusivement éducatives et informatives.

Consultez votre médecin si vous croyez être malade ou composez le 911 pour toute urgence médicale.

CHU Sainte-Justine